Bayer HealthCare to present new data on oncology portfolio at ASCO meeting

Bayer HealthCare Pharmaceuticals Inc.May 16 2013

Bayer HealthCare announced today that new data on the oncology portfolio, including Nexavar® (sorafenib) tablets, Stivarga® (regorafenib) tablets and the recently U.S. Food and Drug Administration (FDA) approved product Xofigo® (radium Ra 223 dichloride) injection will be presented at the 49th Annual Meeting of the American Society of Clinical Oncology (ASCO), May 31 – June 4, in Chicago, IL (USA). These data showcase Bayer's commitment to developing treatments for difficult-to-treat cancers. 

"Bayer's oncology franchise has had a remarkable year of growth since ASCO 2012, receiving two drug approvals from the U.S. Food and Drug Administration in three tumor types with high unmet medical need," said Pamela A. Cyrus , MD, Vice President and Head of U.S. Medical Affairs, Bayer HealthCare Pharmaceuticals. "At this year's ASCO, data presentations on Bayer's products will highlight our continued commitment to making ongoing investments in areas where therapeutic options are very much needed."

Notable studies evaluating Bayer's oncology products and compounds at ASCO include:

Sorafenib

• Sorafenib in locally advanced or metastatic patients with radioactive iodine-refractory differentiated thyroid cancer: The phase III DECISION trial
  • Abstract #4, Plenary Abstract Session
  • Sunday, June 2, 3:20-3:35 PM, N Hall B1 
• Final analysis of GIDEON (Global Investigation of Therapeutic Decisions in Hepatocellular Carcinoma [HCC] and of Its Treatment with Sorafenib [Sor]) in >3000 Sor-treated patients (pts): Clinical findings in pts with liver dysfunction
  • Abstract #4126, General Poster Session: Gastrointestinal (Noncolorectal) Cancer
  • Sunday, June 2, 8:00 - 11:45 AM, S Hall A2

Regorafenib

• Mutational analysis of plasma DNA from patients (pts) in the phase III GRID study of regorafenib (REG) versus placebo (PL) in tyrosine kinase inhibitor (TKI)-refractory GIST: Correlating genotype with clinical outcomes.     
  • Abstract #10503, Oral Abstract Session: Sarcoma
  • Monday, June 3, 3:45-4:00 PM, S100bc
• Results from a phase III trial (GRID) evaluating regorafenib (REG) in metastatic gastrointestinal stromal tumour (GIST): Subgroup analysis of outcomes based on pretreatment characteristics            
  • Abstract #10551, General Poster Session: Sarcoma
  • Saturday, June 1, 1:15-5:00 PM, S Hall A2
• Time profile of adverse events (AEs) from regorafenib (REG) treatment for metastatic colorectal cancer (mCRC) in the phase III CORRECT study
  • Abstract #3637, General Poster Session: Gastrointestinal (Colorectal) Cancer
  • Sunday, June 2, 8:00-11:45 AM, S Hall A2
• Regorafenib (REG) in progressive metastatic colorectal cancer (mCRC): Analysis of age subgroups in the phase III CORRECT trial
  • Abstract #3636, General Poster Session: Gastrointestinal (Colorectal) Cancer
  • Sunday, June 2, 8:00-11:45 AM, S Hall A2
• Regorafenib (REG) in patients with hepatocellular carcinoma (HCC) progressing following sorafenib: An ongoing randomized, double-blind, phase III trial    
  • Abstract #TPS4163, General Poster Session: Gastrointestinal (Noncolorectal) Cancer
  • Sunday, June 2, 8:00-11:45 AM, S Hall A2
• Analysis of plasma protein biomarkers from the CORRECT phase III study of regorafenib for metastatic colorectal cancer      
  • Abstract #3514, Poster Discussion Session: Gastrointestinal (Colorectal) Cancer
  • Tuesday, June 4, 8:00 AM - 12:00 PM, S405

Radium 223 dichloride

• Hematologic safety of Ra-223 dichloride (Ra-223) in castration-resistant prostate cancer (CRPC) patients with bone metastases from the phase III ALSYMPCA trial
  • Abstract #5060, General Poster Session: Genitourinary (Prostate) Cancer
  • Monday, June 3, 8:00 – 11:45 AM, S Hall A2
• Efficacy and safety of radium-223 dichloride (Ra-223) in castration-resistant prostate cancer (CRPC) patients with bone metastases who did or did not receive prior docetaxel (D) in the phase III ALSYMPCA trial
  • Abstract #5068, General Poster Session: Genitourinary (Prostate) Cancer
  • Monday, June 3, 8:00  – 11:45 AM, S Hall A2
• Pain analysis from the phase III randomized ALSYMPCA study with radium-223 dichloride (Ra-223) in castration-resistant prostate cancer (CRPC) patients with bone metastases
  • Abstract #5038, General Poster Session: Genitourinary (Prostate) Cancer
  • Monday, June 3, 8:00 – 11:45 AM, S Hall A2
• Correlation between baseline variables and survival in the radium-223 dichloride (Ra-223) phase III ALSYMPCA trial with attention to total ALP changes
  • Abstract #5080, General Poster Session: Genitourinary (Prostate) Cancer
  • Monday, June 3, 8:00 – 11:45 AM, S Hall A2